Literature DB >> 23876334

Mucopolysaccharidosis IVA: correlation between genotype, phenotype and keratan sulfate levels.

Vũ Chí Dũng1, Shunji Tomatsu, Adriana M Montaño, Gary Gottesman, Michael B Bober, William Mackenzie, Miho Maeda, Grant A Mitchell, Yasuyuki Suzuki, Tadao Orii.   

Abstract

Mucopolysaccharidosis IVA (MPS IVA) is caused by deficiency of N-acetylgalactosamine-6-sulfate sulfatase (GALNS), leading to systemic skeletal dysplasia because of excessive storage of keratan sulfate (KS) in chondrocytes. In an effort to determine a precise prognosis and personalized treatment, we aim to characterize clinical, biochemical, and molecular findings in MPS IVA patients, and to seek correlations between genotype, phenotype, and blood and urine KS levels. Mutation screening of GALNS gene was performed in 55 MPS IVA patients (severe: 36, attenuated: 13, undefined: 6) by genomic PCR followed by direct sequence analysis. Plasma and urine KS levels were measured by ELISA method. Genotype/phenotype/KS correlations were assessed when data were available. Fifty-three different mutations including 19 novel ones (41 missense, 2 nonsense, 4 small deletions, 1 insertion, and 5 splice-site) were identified in 55 patients and accounted for 93.6% of the analyzed mutant alleles. Thirty-nine mutations were associated with a severe phenotype and ten mutations with an attenuated one. Blood and urine KS concentrations in MPS IVA patients were age-dependent and markedly higher than those in age-matched normal controls. Plasma and urine KS levels in MPS IVA patients with the severe phenotype were higher than in those with an attenuated form. This study provides evidence for extensive allelic heterogeneity of MPS IVA. Accumulation of mutations as well as clinical descriptions and KS levels allows us to predict clinical severity more precisely and should be used for evaluation of responses to potential treatment options.
© 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Biomarker; C6S; CDC; Centers for Disease Control and Prevention; Chondroitin-6-sulfate; Cr; Creatinine; DMB; DMSO; GAGs; GALNS; Genotype; Glycosaminoglycans; IMO; IVA Mucopolysaccharidosis IVA; International Morquio Organization; KS; Keratan sulfate; LSD; Lysosomal storage disorder; MPS; Mucopolysaccharidosis IVA; N-acetylgalactosamine-6-sulfate sufatase; Phenotype; dimethylmethylene blue; dimethylsulfoxide

Mesh:

Substances:

Year:  2013        PMID: 23876334      PMCID: PMC3779837          DOI: 10.1016/j.ymgme.2013.06.008

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  35 in total

1.  Incidence of inborn errors of metabolism in British Columbia, 1969-1996.

Authors:  D A Applegarth; J R Toone; R B Lowry
Journal:  Pediatrics       Date:  2000-01       Impact factor: 7.124

2.  Mucopolysaccharidosis IVA mutations in Chinese patients: 16 novel mutations.

Authors:  Zheng Wang; Weimin Zhang; Yun Wang; Yan Meng; Liang Su; Huiping Shi; Shangzhi Huang
Journal:  J Hum Genet       Date:  2010-06-24       Impact factor: 3.172

3.  Determinant factors of spectrum of missense variants in mucopolysaccharidosis IVA gene.

Authors:  Shunji Tomatsu; Adriana M Montaño; Patricia Lopez; Georgeta Trandafirescu; Monica A Gutierrez; Hirotaka Oikawa; Tatsuo Nishioka; Matheus B Vieira; Tadao Orii; Akihiko Noguchi
Journal:  Mol Genet Metab       Date:  2006-07-11       Impact factor: 4.797

4.  Mutation and polymorphism spectrum of the GALNS gene in mucopolysaccharidosis IVA (Morquio A).

Authors:  Shunji Tomatsu; Adriana M Montaño; Tatsuo Nishioka; Monica A Gutierrez; Olga M Peña; Georgeta G Tranda Firescu; Patricia Lopez; Seiji Yamaguchi; Akihiko Noguchi; Tadao Orii
Journal:  Hum Mutat       Date:  2005-12       Impact factor: 4.878

5.  Effect of 'attenuated' mutations in mucopolysaccharidosis IVA on molecular phenotypes of N-acetylgalactosamine-6-sulfate sulfatase.

Authors:  A M Montaño; K Sukegawa; Z Kato; R Carrozzo; P Di Natale; E Christensen; K O Orii; T Orii; N Kondo; S Tomatsu
Journal:  J Inherit Metab Dis       Date:  2007-09-17       Impact factor: 4.982

Review 6.  Mutations and polymorphisms in GUSB gene in mucopolysaccharidosis VII (Sly Syndrome).

Authors:  Shunji Tomatsu; Adriana M Montaño; Vu Chi Dung; Jeffrey H Grubb; William S Sly
Journal:  Hum Mutat       Date:  2009-04       Impact factor: 4.878

7.  Growth charts for patients affected with Morquio A disease.

Authors:  Adriana M Montaño; Shunji Tomatsu; Ana Brusius; Mary Smith; Tadao Orii
Journal:  Am J Med Genet A       Date:  2008-05-15       Impact factor: 2.802

Review 8.  Incidence of the mucopolysaccharidoses in Western Australia.

Authors:  John Nelson; June Crowhurst; Bill Carey; Lawrence Greed
Journal:  Am J Med Genet A       Date:  2003-12-15       Impact factor: 2.802

9.  Prevalence of lysosomal storage disorders.

Authors:  P J Meikle; J J Hopwood; A E Clague; W F Carey
Journal:  JAMA       Date:  1999-01-20       Impact factor: 56.272

10.  International Morquio A Registry: clinical manifestation and natural course of Morquio A disease.

Authors:  A M Montaño; S Tomatsu; G S Gottesman; M Smith; T Orii
Journal:  J Inherit Metab Dis       Date:  2007-03-08       Impact factor: 4.750

View more
  24 in total

1.  Chondroitin 6-Sulfate as a Novel Biomarker for Mucopolysaccharidosis IVA and VII.

Authors:  Tsutomu Shimada; Shunji Tomatsu; Eriko Yasuda; Robert W Mason; William G Mackenzie; Yuniko Shibata; Francyne Kubaski; Roberto Giugliani; Seiji Yamaguchi; Yasuyuki Suzuki; Kenji Orii; Tadao Orii
Journal:  JIMD Rep       Date:  2014-05-22

2.  Non-invasive pulmonary function test on Morquio patients.

Authors:  Francyne Kubaski; Shunji Tomatsu; Pravin Patel; Tsutomu Shimada; Li Xie; Eriko Yasuda; Robert Mason; William G Mackenzie; Mary Theroux; Michael B Bober; Helen M Oldham; Tadao Orii; Thomas H Shaffer
Journal:  Mol Genet Metab       Date:  2015-06-23       Impact factor: 4.797

3.  Di-sulfated Keratan Sulfate as a Novel Biomarker for Mucopolysaccharidosis II, IVA, and IVB.

Authors:  Tsutomu Shimada; Shunji Tomatsu; Robert W Mason; Eriko Yasuda; William G Mackenzie; Jobayer Hossain; Yuniko Shibata; Adriana M Montaño; Francyne Kubaski; Roberto Giugliani; Seiji Yamaguchi; Yasuyuki Suzuki; Kenji E Orii; Toshiyuki Fukao; Tadao Orii
Journal:  JIMD Rep       Date:  2015-02-25

4.  Effect of enzyme replacement therapy on the growth of patients with Morquio A.

Authors:  Caitlin Doherty; Molly Stapleton; Matthew Piechnik; Robert W Mason; William G Mackenzie; Seiji Yamaguchi; Hironori Kobayashi; Yasuyuki Suzuki; Shunji Tomatsu
Journal:  J Hum Genet       Date:  2019-04-24       Impact factor: 3.172

Review 5.  Advances in glycosaminoglycan detection.

Authors:  Shaukat A Khan; Robert W Mason; Hironori Kobayashi; Seiji Yamaguchi; Shunji Tomatsu
Journal:  Mol Genet Metab       Date:  2020-03-27       Impact factor: 4.797

6.  Molecular testing of 163 patients with Morquio A (Mucopolysaccharidosis IVA) identifies 39 novel GALNS mutations.

Authors:  A Morrone; K L Tylee; M Al-Sayed; A C Brusius-Facchin; A Caciotti; H J Church; M J Coll; K Davidson; M J Fietz; L Gort; M Hegde; F Kubaski; L Lacerda; F Laranjeira; S Leistner-Segal; S Mooney; S Pajares; L Pollard; I Ribeiro; R Y Wang; N Miller
Journal:  Mol Genet Metab       Date:  2014-03-20       Impact factor: 4.797

Review 7.  Pathogenesis and treatment of spine disease in the mucopolysaccharidoses.

Authors:  Sun H Peck; Margret L Casal; Neil R Malhotra; Can Ficicioglu; Lachlan J Smith
Journal:  Mol Genet Metab       Date:  2016-06-04       Impact factor: 4.797

Review 8.  Mechanistic and therapeutic overview of glycosaminoglycans: the unsung heroes of biomolecular signaling.

Authors:  Khushboo Gulati; Krishna Mohan Poluri
Journal:  Glycoconj J       Date:  2015-12-03       Impact factor: 2.916

9.  Computational analysis of human N-acetylgalactosamine-6-sulfate sulfatase enzyme: an update in genotype-phenotype correlation for Morquio A.

Authors:  Sergio Olarte-Avellaneda; Alexander Rodríguez-López; Carlos Javier Alméciga-Díaz; Luis Alejandro Barrera
Journal:  Mol Biol Rep       Date:  2014-10-07       Impact factor: 2.316

10.  Enzyme replacement therapy for treating mucopolysaccharidosis type IVA (Morquio A syndrome): effect and limitations.

Authors:  Shunji Tomatsu; Kazuki Sawamoto; Tsutomu Shimada; Michael B Bober; Francyne Kubaski; Eriko Yasuda; Robert W Mason; Shaukat Khan; Carlos J Alméciga-Díaz; Luis A Barrera; William G Mackenzie; Tadao Orii
Journal:  Expert Opin Orphan Drugs       Date:  2015-10-29       Impact factor: 0.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.